Abstract
Gambian human African trypanosomiasis (gHAT), a neglected tropical disease caused by a parasite transmitted by tsetse flies, once inflicted over 30,000 annual cases and resulted in half a million deaths in the late twentieth century. An international gHAT control program has reduced cases to under 1,000 annually, encouraging the World Health Organization to target the elimination of gHAT transmission by 2030. This requires adopting innovative disease control approaches in foci where transmission persists. Since the last decade, case detection and treatment, the mainstay of controlling the disease, is supplemented by vector control using Tiny Targets, small insecticide-treated screens, which attract and kill tsetse. The advantages of Tiny Targets lie in their relatively low cost, easy deployment, and effectiveness.
The Democratic Republic of Congo (DRC), bearing 65% of the 799 gHAT cases reported globally in 2022, introduced Tiny Targets in 2015. This study estimates the annual cost of vector control using Tiny Targets in a health district in the DRC and identifies the main cost drivers. Economic and financial costs, collected from the provider’s perspective, were used to estimate the average cost of tsetse control expressed as cost (i) per target used, (ii) per target deployed, (iii) linear kilometre of river controlled, and (iv) square kilometres protected by vector control. Sensitivity analyses were conducted on key parameters for results robustness.
The estimated annual economic cost for protecting an area of 1,925 km² was 120,000 USD. This translates to 5.3 USD per target used each year, 11 USD per target deployed in the field, 573 USD per linear km treated, and 62 USD per km² protected. These costs in the DRC are comparable to those in other countries. The study provides valuable information for practitioners and policymakers aiding them in making rational, evidence-based decisions regarding cost-effective strategies to control gHAT.
Author Summary In the fight against Gambian human African trypanosomiasis (gHAT), a devastating disease transmitted by tsetse flies, significant progress has been made through international efforts. Despite the annual cases being reduced to under 1,000, the World Health Organization aims to eliminate gHAT transmission by 2030. A key component of this strategy involves innovative approaches, such as the use of Tiny Targets – small, cost-effective, insecticide-treated screens that attract and kill tsetse flies. This study focuses on the Democratic Republic of Congo (DRC), which bears a substantial burden of gHAT cases, estimating the annual cost of vector control using Tiny Targets in a specific health district. The analysis, conducted from the provider’s perspective, reveals an annual economic cost of 120,000 USD for protecting a 1,925 km² area. This translates to 5.3 USD per target used, 11 USD per target deployed, 573 USD per linear km treated, and 62 USD per km² protected. These findings, comparable to costs in other countries, offer valuable insights for practitioners and policymakers, guiding evidence-based decisions on cost-effective strategies for gHAT control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data available in supporting files
